COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Racotumomab in Patients With High-risk Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02998983
Recruitment Status : Recruiting
First Posted : December 21, 2016
Last Update Posted : March 9, 2020
Information provided by (Responsible Party):
Laboratorio Elea Phoenix S.A.

Brief Summary:

This clinical trial will be carried out in children diagnosed with high-risk neuroblastoma that have achieved a complete or very good partial response after standard therapy. An additional cohort of children who could not achieve these response criteria or that relapsed after standard therapy but do not have progressive disease will receive Racotumomab together with metronomic chemotherapy.

The main objectives of this study are to determine the immune response after one-year duration immunization with Racotumomab, to describe the response of Racotumomab therapy in minimal residual disease (MRD) in bone marrow and to describe the toxicity profile of Racotumomab.

Condition or disease Intervention/treatment Phase
Neuroblastoma Drug: Racotumomab Phase 2

Detailed Description:

Neuroblastoma is the most common extra-cranial tumor in childhood but prognosis is still poor, even with the advances in its treatment.

New therapeutic strategies have been examined, and several immunotherapeutic approaches, including combined therapy with monoclonal antibodies (anti-GD2), intravenous interleukin-2 (Il-2) and intravenous granulocyte-macrophage colony-stimulating factor (GM-CSF), and anti-idiotype vaccines are currently being assessed.

Racotumomab is an anti-idiotype antibody capable of inducing anti-N-glycolyl GM3 antibodies in patients with neuroblastoma.

The expression of the ganglioside N-glycolyl GM3 was shown in neuroblastoma and this expression could be useful as a specific target for immunotherapy.

Ractoumomab will be administered once standard therapy for neuroblastoma has been completed.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Multicenter, Phase II Immunotherapy Study With Racotumomab in Patients With High-risk Neuroblastoma
Study Start Date : November 2016
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Neuroblastoma

Arm Intervention/treatment
Experimental: Racotumomab
Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
Drug: Racotumomab

Primary Outcome Measures :
  1. Number of participants who elicit an immune response to a one-year immunization schedule of racotumomab in a cohort study of patients with high-risk neuroblastoma. [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Number of participants in whom minimally disseminated disease in the bone marrow decreases or disappears with a one-year immunization schedule of racotumomab compared to baseline values at study entry. [ Time Frame: 1 year ]
  2. Number of Participants With Treatment-Related Adverse Events as assessed by CTCAE v4.0 after a one-year immunization schedule of racotumomab when administered alone or together with onco-specific metronomic chemotherapy therapy. [ Time Frame: 1 year ]
  3. Pattern of expression of N-Glycolyl-GM3 gangliosides in tumor samples obtained at disease diagnosis and during follow up if available. [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Informed Consent or written child assent, if applicable, prior to any specific procedure of the study.
  2. Aged ≥ 1 year old and ≤ 12 years old at the time of diagnose.
  3. High-risk neuroblastoma diagnose according to the International Neuroblastoma Risk Group Staging System (INRGSS) (Annex I).
  4. Patients who have received complete chemotherapy, radiotherapy (if applicable) and autologous hematopoietic stem cell transplantation (if applicable) not earlier than 30 days prior to being included in the study, and patients of Group I who have completed therapy with cis retinoic acid or other maintenance onco-specific therapy using the standard dose for neuroblastoma treatment. .
  5. Use of concomitant metronomic chemotherapy by patients of Group II is considered acceptable.
  6. For patients belonging to other risk group who have relapsed or progressed, the period between the beginning of chemotherapy for the treatment of high-risk neuroblastoma and the inclusion of patients must not exceed 12 months.
  7. Partial or complete remission status, very good partial remission or stable disease (pursuant to the International Neuroblastoma Response Criteria) at the time of inclusion (Annex IV).
  8. Assessment of the disease must be conducted within 30 days prior to inclusion.
  9. Additional studies supporting the response to treatment at the time of inclusion are required.
  10. Normal organ functions according to the following parameters:

    • Adequate cardiac function as defined below:
    • Electrocardiogram (ECG) 30 days prior to inclusion without substantial anomalies.
    • Electrocardiogram (ECG) 30 days prior to inclusion with fractional shortening ≥27%
    • Adequate bone marrow functions defined as follows:
    • Neutrophil ≥1000/mm3 with no use of stimulating factor for at least 2 weeks prior to inclusion.
    • Lymphocytes ≥500/mm3
    • Platelets ≥ 50000/mm3.
    • Adequate hepatic functions defined as follows:
    • Direct bilirubin ≤1.5 x upper limit of normal (ULN)
    • AST/ALT ≤ 5 x ULN
    • Adequate renal function defined as follows:
    • Creatinine Clearance ≥70 ml/min/1.73m2 or serum Creatinine (Cr) as per age/gender.
  11. Known history of Hepatitis B or C seropositivity with studies showing hepatic function results within acceptable limits may be eligible.
  12. Negative HIV serology.
  13. Pregnancy test-negative for women of childbearing potential.
  14. No previous Racotumomab therapy.
  15. No previous intravenous immunoglobulin therapy for at least one month prior to the beginning of treatment.
  16. Lansky Scale ≥ 50 (Annex II)
  17. Patients with extended bone metastasis in cranial vault or cranial base due to proximity may be considered eligible.

Exclusion Criteria:

In order to be included, patients must not meet the following criteria:

  1. Neuroblastoma as progressive disease at the time of the beginning of the study.
  2. Patients with known hypersensitivity to any of the components of the investigational drug.
  3. Pregnant or breastfeeding patients.
  4. Patients who have received other investigational drugs or Racotumomab within 30 days prior to their inclusion in the protocol.
  5. History of autoimmune diseases, congenital immunodeficiencies or uncontrolled chronic diseases.
  6. Acute allergy disorders or history of severe allergy reactions.
  7. History of demyelinating disease or inflammatory disease of the central nervous system or the peripheral nervous system.
  8. Patients with any of the following uncontrolled intercurrent disease:

    • Active infectious diseases
    • Uncontrolled cardiac disease: symptomatic congestive heart failure, serious cardiac arrhythmia.
    • Known hepatic disease: cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
    • Convulsions not controlled with any anticonvulsant medication.
  9. Other malignancies after adequate therapy showing a disease-free period for more than 5 years.
  10. Patients receiving chronic therapy with systemic steroids and other immunosuppressive agents. Topical steroids and inhaled corticosteroids are permitted.
  11. History of positive HIV serology.
  12. Clinically symptomatic metastasis in central nervous system.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02998983

Layout table for location information
Hospital Universitario Austral Recruiting
Pilar, Buenos Aires, Argentina, 1629
Contact: Guillermo Chantada, MD    +542304482831   
Prof. Dr. J. P. Garrahan National Children's Hospital Recruiting
Buenos Aires, Argentina, 1245
Contact: Walter Cacciavillano, MD   
Principal Investigator: Walter Cacciavillano, MD         
Sponsors and Collaborators
Laboratorio Elea Phoenix S.A.
Layout table for investigator information
Principal Investigator: Walter Cacciavillano, MD Prof. Dr. J. P. Garrahan National Children's Hospital
Layout table for additonal information
Responsible Party: Laboratorio Elea Phoenix S.A. Identifier: NCT02998983    
Other Study ID Numbers: AR-RACO-2-16
First Posted: December 21, 2016    Key Record Dates
Last Update Posted: March 9, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue